EUVIMEDEUVIMED entdecken
Crossref

Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways

Xi Xiao, Mengke Chen, Ye Sang, Junyu Xue, Ke Jiang, Yulu Chen, Luyao Zhang, Shuang Yu, Weiming Lv, Yanbing Li, Rengyun Liu iD, Haipeng Xiao

Thyroid® · 2023

DOI: 10.1089/thy.2023.0157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2023. Verfasst von Xi Xiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Thyroid Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, “100 Top Talents Program” of Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aberrant expression of oncogenes and/or tumor suppressor genes (TSGs) drives the tumorigenesis and development of thyroid cancer. We investigated the expression and function of a member of the activating transcription factor (ATF)/cAMP-responsive element-binding protein (CREB) transcription factor (TF) family, ATF3, in thyroid cancer.

Methods

Data from 80 patients with papillary thyroid cancer (PTC) in the First Affiliated Hospital of Sun Yat-sen University and 510 PTC samples in The Cancer Genome Atlas thyroid cancer database were utilized for gene expression and prognosis analyses. The survival data were analyzed by Kaplan–Meier curves and Cox regression with adjustment for age, sex, multilocality, extrathyroidal extension, lymph metastases, and history of neoadjuvant treatment. DNA methylation was analyzed by methylation-specific polymerase chain reaction (PCR) and bisulfite sequencing PCR. TFs binding to ATF3 promoter were identified by DNA pull-down combined with mass spectrum assay, and confirmed by quantitative PCR (qPCR), luciferase reporter assay, and chromatin immunoprecipitation (ChIP)-qPCR. We conducted functional assays in vitro and in a xenograft mouse model to evaluate the function of ATF3 in thyroid cancer. Integrated analyses based on RNA sequencing, ChIP-seq, and CUT&Tag assays were performed to explore the mechanisms underlying the function of ATF3.

Results

ATF3 was significantly downregulated in PTC and patients with low ATF3 expression had reduced progression-free survival (adjusted hazard ratio = 0.50 [CI 0.26–0.98], p = 0.043). DNA hypermethylation in ATF3 promoter disrupted the binding of SP1 and MYC-MAX, leading to inactivation of the gene. ATF3 functioned as a TSG by inhibiting the proliferation and mobility of thyroid cancer cells. And ATF3 regulated the expression of a number of genes by binding to the regulatory elements of them, particularly for genes in MAPK and PI3K/AKT pathways. Among these target genes, filamin C was positively regulated by ATF3 and associated with a more favorable thyroid cancer prognosis, while dual specificity phosphatase 10, fibronectin-1, tenascin C, and CREB5 were negatively regulated by ATF3 and associated with a poorer prognosis.

Conclusions

We observed that the promoter DNA hypermethylation decreased the expression of ATF3, which in turn promoted the progression of thyroid cancer, at least partially, by directly regulating prognosis-related genes in the MAPK and PI3K/AKT pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktThyroid NeoplasmsHumansAnimalsMicePhosphatidylinositol 3-KinasesPrognosisThyroid Cancer, PapillaryDNA MethylationDNAGene Expression Regulation, NeoplasticCell Line, TumorCell ProliferationActivating Transcription Factor 3

Stichwörter der Autor:innen

ATF3DNA methylationthyroid cancertranscription factor

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesDNAATF3 protein, humanActivating Transcription Factor 3

Autor:innen und Institutionen

  • Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Breast and Thyroid Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Rengyun Liu

Förderung

  • National Natural Science Foundation of China
  • “100 Top Talents Program” of Sun Yat-sen University

Zitieren

APA

Xiao, X., Chen, M., Sang, Y., Xue, J., Jiang, K., Chen, Y., Zhang, L., Yu, S., Lv, W., Li, Y., Liu, R., & Xiao, H. (2023). Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways. Thyroid®. https://doi.org/10.1089/thy.2023.0157

Vancouver

Xiao X, Chen M, Sang Y, Xue J, Jiang K, Chen Y, et al. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways. Thyroid®. 2023. doi:10.1089/thy.2023.0157

BibTeX
@article{Xiao2023,
  author = {Xiao, Xi and Chen, Mengke and Sang, Ye and Xue, Junyu and Jiang, Ke and Chen, Yulu and Zhang, Luyao and Yu, Shuang and Lv, Weiming and Li, Yanbing and Liu, Rengyun and Xiao, Haipeng},
  title = {Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways},
  journal = {Thyroid®},
  year = {2023},
  doi = {10.1089/thy.2023.0157}
}
Kostenlos starten →